Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A The assessment report for this appraisal was prepared by Aberdeen HTA Group:

  • Ford J, Cummins E, Sharma P et al. Systematic review of the clinical and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Aberdeen HTA Group, Institute of Applied Health Sciences, University of Aberdeen, 2011

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I, II and III were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I Manufacturers/sponsors:

  • Amgen

II Professional/specialist and patient/carer groups:

  • Breakthrough Breast Cancer

  • Breast Cancer Care

  • Macmillan Cancer Support

  • Prostate Cancer Support Federation

  • British Orthopaedic Oncology Society

  • British Prostate Group

  • British Psychosocial Oncology Society

  • British Society for Haematology

  • British Uro-Oncology Group

  • Cancer Research UK

  • Royal College of Nursing

  • Royal College of Physicians

III Other consultees:

  • Department of Health

  • Welsh Government

IV Commentator organisations (without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Services

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Novartis

  • British Prostate Group

  • MRC Clinical Trials Unit

  • Prostate Action

  • Aberdeen Health Technology Assessment Group

  • National Institute for Health Research Health Technology Assessment Programme

  • National Collaborating Centre for Cancer

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on Denosumab for the treatment of bone metastases from solid tumours by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Amit Bahl, Consultant Clinical Oncologist, nominated by British Uro-oncology Group – clinical specialist

  • Dr David Dodds, Consultant Oncologist, nominated by Healthcare Improvement Scotland (Gave last minute apologies to the Meeting) – clinical specialist

  • Dr Stephen Harland, Consultant Medical Oncologist, nominated by Prostate Action – clinical specialist

  • Tara Beaumont, Clinical Nurse Specialist, nominated by Breast Cancer Care – patient expert

  • David Dodds, nominated by Prostate Cancer Support Federation (unfortunately unable to attend the meeting) – patient expert

D Representatives from the following manufacturers/sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Amgen

  • National Institute for Health and Care Excellence (NICE)